Psoriasis is a systemic chronic skin disorder characterized by excessive keratinocyte proliferation that results into thickened scaly plaques, itching and inflammatory changes in the epidermis and dermis. It is transmitted genetically but can be provoked by environmental factors.
It is found in approximately 2% of the population that primarily affects the skin and joints.
It is associated with other inflammatory disorders and autoimmune diseases (eg psoriatic arthritis, inflammatory bowel disease, coronary artery disease).
Generally, it begins as red scaling papules that coalesce to form round-to-oval plaques. The rashes are often pruritic and may be painful.
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
The risk of psoriasis is higher among current smokers, particularly those who smoke >25 cigarettes per day and for >20 pack-years, according to a Taiwanese population-based cohort study. On the other hand, alcohol consumption shows no significant association with psoriasis development.
Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.
Interleukin 17A (IL-17A) antagonist ixekizumab demonstrates superior efficacy and similar safety outcomes compared with IL-12/23 inhibitor ustekinumab through 52 weeks of treatment, according to the results of a phase III trial.
Treatment with secukinumab results in improved endothelial function in patients with plaque psoriasis, with the improvements translating to reduced risk of cardiovascular disease, according to data from the CARIMA trial.
New drug applications approved by US FDA as of 01 - 15 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
More patients with moderate-to-severe psoriasis who were treated with the tyrosine kinase 2 (TYK2) inhibitor BMS-986165 achieved improvements in their condition compared with placebo recipients, according to a recent phase II study.
Two phase III studies have demonstrated the superiority of the selective interleukin-23p19 inhibitor risankizumab over ustekinumab or placebo in helping patients with moderate-to-severe chronic plaque psoriasis reduce the severity of their condition.